A potent activator of PPARα and γ reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits

Atherosclerosis

Volumn 178, Issue 1, 2005, Pages 1-7

  Seki, Naoto ^a   Bujo, Hideaki ^a   Jiang, Meizi ^a   Shibasaki, Manabu ^a   Takahashi, Kazuo ^a   Hashimoto, Naotake ^a   Saito, Yasushi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Hypercholesterolemia; Intimal thickning; Peroxisome proliferator activated receptors; Vascular wall

Indexed keywords

GLUCOSE; IMIGLITAZAR; INTERLEUKIN 1BETA; LIPID; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; (E) 4 (4 ((5 METHYL 2 PHENYL 1,3 OXAZOL 4 YL)METHOXY)BENZYLOXYIMINO) 4 PHENYLBUTYRIC ACID; (E)-4-(4-((5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)METHOXY)BENZYLOXYIMINO)-4-PHENYLBUTYRIC ACID; BUTYRIC ACID DERIVATIVE; CCL2 PROTEIN, HUMAN; OXAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CELL ADHESION; CELL COUNT; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; BLOOD VESSEL; CAROTID ARTERY; CELL DIVISION; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; HYPERPLASIA; INTIMA; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD VESSELS; BUTYRIC ACIDS; CAROTID ARTERIES; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CCL2; ENDOTHELIAL CELLS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERPLASIA; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OXAZOLES; PPAR ALPHA; PPAR GAMMA; RABBITS; TUNICA INTIMA;

EID: 10044241682     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.08.015     Document Type: Article

References (28)

1. W.A. Hsueh, and R.E. Law PPARγ and atherosclerosis: effects on cell growth and movement Arterioscler. Thromb. Vasc. Biol. 21 2001 1891 1895
2. M. Ricote, J. Huang, and L. Fajas Expression of the peroxisome proliferator-activated receptor gamma (PPAR-γ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low-density lipoprotein Proc. Natl. Acad. Sci. U.S.A. 23 1998 7614 7619
3. R.E. Law, S. Goetz, and X.P. Xi Expression and function of PPAR-γ in rat and human vascular smooth muscle cells Circulation 101 2000 1311 1318
4. B.R. Kwak, S. Myit, and F. Mulhaupt PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells Circ. Res. 90 22 2002 356 362
5. D.S. Calnek, L. Mazzella, S. Roser, J. Roman, and C.M. Hart Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells Arterioscler. Thromb. Vasc. Biol. 23 2003 52 57
6. M. Igarashi, Y. Takeda, and N. Ishibashi Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization Horm. Metab. Res. 29 1997 444 449
7. A.R. Collins, W.P. Meehan, and U. Kintscher Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice Arterioscler. Thromb. Vasc. Bio. 21 2001 365 371
8. A.C. Li, K.K. Brown, and M.J. Silvestre Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J. Clin. Invest. 106 2000 523 531
9. U. Kintscher, C. Lyon, and S. Wakino PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4 Circ. Res. 91 2002 35 44
10. G. Chinetti, S. Lestavel, J.C. Fruchart, V. Clavey, and B. Staels Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages Circ. Res. 92 2003 212 217
11. H. Imoto, Y. Sugiyama, H. Kimura, and Y. Momose Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents Chem. Pharm. Bull. (Tokyo) 51 2003 138 151
12. J. Sakamoto, H. Kimura, and S. Moriyama Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone Biochem. Biophys. Res. Commun. 278 2000 704 711
13. Y. Zhu, H. Bujo, and H. Yamazaki Enhanced expression of the LDL receptor family member LR11 increases migration of smooth muscle cells in vitro Circulation 105 2002 1830 1836
14. T. Kanaki, H. Bujo, and S. Hirayama Expression of LR11, a mosaic LDL receptor family member, is markedly increased in atherosclerotic lesions Arterioscler. Thromb. Vasc. Biol. 19 1999 2687 2695
15. K. Yokote, N. Morisaki, and M. Zenibayashi The phospholipase-A2 reaction leads to increased monocyte adhesion of endothelial cells via the expression of adhesion molecules Eur. J. Biochem. 217 1993 723 729
16. Zhu Y, Bujo H, Yamazaki H, et al. LR11, an LDL receptor gene family member, is a novel regulator of smooth muscle cell migration. Circ Res 2004, Epub ahead of print.
17. E.D. Rosen, and B.M. Spiegelman Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache J. Clin. Invest. 106 2000 629 631
18. C.K. Glass Antiatherogenic effects of thiazolidinediones? Arterioscler. Thromb. Vasc. Biol. 21 2001 295 296
19. R.E. Law, W.P. Meehan, and X.P. Xi Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia J. Clin. Invest. 98 1996 1897 1905
20. T. Yoshimoto, M. Naruse, and H. Shizume Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy Atherosclerosis 145 1999 333 340
21. M. Igarashi, A. Hirata, and H. Yamaguchi Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth Metabolism 50 2001 955 962
22. M. Ishibashi, K. Egashira, and K. Hiasa Antiinflammatory and antiarteriosclerotic effects of pioglitazone Hypertension 40 2002 687 693
23. X. Xin, S. Yang, J. Kowalski, and M.E. Gerritsen Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo J. Biol. Chem. 274 1999 9116 9121
24. T. Yoshimoto, M. Naruse, and H. Shizume Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy Atherosclerosis 145 1999 333 340
25. N. Marx, B. Kehrle, and K. Kohlhammer PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis Circ. Res. 90 2002 703 710
26. L. Nagy, P. Tontonoz, J.G. Alvarez, H. Chen, and R.M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma Cell 93 1998 229 240
27. P. Tontonoz, L. Nagy, J.G. Alvarez, V.A. Thomazy, and R.M. Evans PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 93 1998 241 252
28. K. Egashira Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1 Hypertension 41 2003 834 841